Strides Pharma Science Ltd Quarterly Results
Q3 FY25-26 Results Summary
Revenue
The revenue stands at ₹1,194.65 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 2.14 per cent from ₹1,220.83 crore. This corresponds to a year-on-year *(YoY) growth of 3.55 per cent.
Operating Profit
Operating Profit stands at ₹232.62 crore, reflecting a quarter-on-quarter *(QoQ) increase of 4.90 per cent from ₹221.75 crore. This corresponds to a year-on-year *(YoY) growth of 11.90 per cent.
PBDT
PBDT stands at ₹296.11 crore, reflecting a quarter-on-quarter *(QoQ) increase of 46.05 per cent from ₹202.75 crore. This corresponds to a year-on-year *(YoY) growth of 82.49 per cent.
Profit Before Tax
Profit Before Tax stands at ₹245.49 crore, reflecting a quarter-on-quarter *(QoQ) increase of 60.34 per cent from ₹153.11 crore. This corresponds to a year-on-year *(YoY) growth of 115.64 per cent.
Net Profit
Net Profit stands at ₹208.13 crore, reflecting a quarter-on-quarter *(QoQ) increase of 58.25 per cent from ₹131.52 crore. This represents a 131.15 per cent year-on-year *(YoY) growth for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Strides Pharma Science Ltd News
Strides Pharma Science Ltd Earnings
- YOY
- QOQ
Strides Pharma Science Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Strides Pharma Science Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Strides Pharma Science Ltd Financial Reports
Strides Pharma Science Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Strides Pharma | 0.79% | -0.16% | 15.14% | 34.60% | 19.49% | 73.35% |
| Concord Biotech | -1.03% | -3.42% | 8.99% | -2.70% | -24.34% | -25.57% |
| Sanofi Consumer | 5.89% | 1.78% | 3.23% | 15.69% | 3.80% | -3.35% |
| Corona Remedies | 4.32% | 3.96% | 13.09% | 15.40% | 23.85% | 23.85% |
| Viyash Scientific | 3.23% | 5.84% | 10.33% | 9.39% | -6.40% | 31.59% |
| Marksans Pharma | 0.90% | 2.07% | 12.91% | 13.17% | 5.04% | -15.60% |
| Shilpa Medicare | 3.09% | 3.19% | 8.59% | 36.84% | 23.04% | 25.90% |
Company Info
Company Information
Chairman & Non Executive Dir. : Arun Kumar
Executive Director / WTD / Managing Director / CEO : Badree Komandur
Independent Non Exe. Director : Kausalya Santhanam
Independent Non Exe. Director : Mukta Malik Arora
Independent Non Exe. Director : Homi R Khusrokhan
Independent Non Exe. Director : Ameet Hariani
Independent Non Exe. Director : Subir Chakraborty
Executive Director / Whole Time Director : Aditya Kumar
Company Sec. & Compli. Officer : Manjula Ramamurthy